Abstract
Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.
| Original language | English |
|---|---|
| Pages (from-to) | 79-87 |
| Number of pages | 9 |
| Journal | Oncology Reviews |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jun 2009 |
Fingerprint
Keywords
- Angiogenesis
- Chemotherapy
- Metastasis
- Neuroendocrine tumours
- Target therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
From biology to clinical experience : Evolution in the knowledge of neuroendocrine tumours. / Bajetta, Emilio; Procopio, Giuseppe; Pusceddu, Sara; Pietrantonio, Filippo; Milione, Massimo; MacCauro, Marco; Verzoni, Elena; Guadalupi, Valentina; Platania, Marco.
In: Oncology Reviews, Vol. 3, No. 2, 06.2009, p. 79-87.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - From biology to clinical experience
T2 - Evolution in the knowledge of neuroendocrine tumours
AU - Bajetta, Emilio
AU - Procopio, Giuseppe
AU - Pusceddu, Sara
AU - Pietrantonio, Filippo
AU - Milione, Massimo
AU - MacCauro, Marco
AU - Verzoni, Elena
AU - Guadalupi, Valentina
AU - Platania, Marco
PY - 2009/6
Y1 - 2009/6
N2 - Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.
AB - Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.
KW - Angiogenesis
KW - Chemotherapy
KW - Metastasis
KW - Neuroendocrine tumours
KW - Target therapy
UR - http://www.scopus.com/inward/record.url?scp=67650665487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650665487&partnerID=8YFLogxK
U2 - 10.1007/s12156-009-0011-x
DO - 10.1007/s12156-009-0011-x
M3 - Article
AN - SCOPUS:67650665487
VL - 3
SP - 79
EP - 87
JO - Oncology Reviews
JF - Oncology Reviews
SN - 1970-5557
IS - 2
ER -